0820 GMT - The medical technology sector is set for another volatile year in 2025, with investors looking for "safe havens" with less exposure to tariff risks and resilience to macro uncertainty, Berenberg analysts say. Swiss-American Alcon and the U.K's Hikma, who manufacture a large proportion of their products where they are sold, have some degree of pricing power to offset cost inflation as a result of tariffs, the analysts write in a note. Investors' worries center on the risk of a potential U.S. recession due to tariffs that would lead to falling demand for med-techs with significant consumer exposure in the U.S., such as Switzerland's Straumann and Germany's Carl Zeiss Meditec, they say. Despite the market turmoil, investor interest in the sector remains high, the analysts add.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 08, 2025 04:20 ET (08:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.